COMPANY PROFILE

MedDay

Explore full profile

Therapeutics for the treatment of neuro-metabolic diseases

Paris, FranceFounded 2011Biotech & Life Sciences

Valuation $100–250M Last recorded · 2016

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About MedDay

MedDay Pharmaceuticals operates in the biopharmaceutical sector, focusing on the research and development of treatments for neurodegenerative diseases. Utilizing their proprietary metabolomics platform, SPECMET, MedDay identifies specific metabolic signatures in central nervous system disorders, which aids in the development of new therapeutic solutions. The company primarily serves patients suffering from neurodegenerative conditions, healthcare providers, and research institutions. MedDay's business model revolves around the discovery and commercialization of novel drugs, generating revenue through product sales, partnerships, and licensing agreements. The market it operates in is highly specialized, targeting unmet medical needs in the neurology field. MedDay's innovative approach and strong scientific advisory board position it as a leader in neurodegenerative disease research.

MoreLess Source: Dealroom company data

At a glance

Status: Closed
Founded: 2011
Headquarters: Paris, France
Employees: 36
Open positions: None listed
Dealroom signal: 0.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Neurology, Spinout, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, observatoire industrial tech, DT and LS, observatoire healthtech, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Apr 2016	$37M	$150M	Andera Partners · Bpifrance · Sofinnova Partners · InnoBio	—
EARLY VC✓Equity / VC	Apr 2013	$8.8M	$35M	Bpifrance · Sofinnova Partners · CDC Enterprises	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

MedDay website traffic

Latest recorded traffic for MedDay is 280 monthly website visits, up 33.3% over the last three months.

Latest monthly visits280 3-month web change+33.3%

Monthly website visitsJun 2015–Sep 2022

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
LTLys TherapeuticsInnovative biotherapies targeting neurological diseases with a focus on stroke and multiple sclerosis	Caen, France	Operational	15	$13M	$13M
TPTHX PharmaPharmaceuticals for rare neurological diseases and disorders.	Lyon, France	Operational
VEVect-HorusDesigning and developing peptide-based vectors that facilitate the delivery of drugs or imaging agents into organs	Marseille, France	Operational
GBGenSight BiologicsDevelops innovative therapies for mitochondrial and neurodegenerative diseases	Paris, France	Operational
IPInBrain PharmaInnovative solutions against neurodegenerative diseases	Loos, France	Operational
ALAlzprotectBiopharmaceutical company which develop new bioactive molecules for the treatment of neurodegenerative diseases	Loos, France	Operational
ABActicor BiotechSafe and effective treatment of stroke	Paris, France	Operational
BTBrink TherapeuticsUnlocking in vivo cell therapy with the next generation of gene editing technology	Saint-Mandé, France	Operational